ADC Therapeutics (ADCT) Gross Margin (2021 - 2026)
ADC Therapeutics' (ADCT) quarterly Gross Margin came in at 89.07% in Q2 2026, down 649.0% year-over-year from 16.22% in Q2 2025, and up 6.83% quarter-over-quarter from 83.37% in Q1 2026.
Powered by 
Analysis
ADC Therapeutics (ADCT) Gross Margin (2021 - 2026) Analysis & Trends
ADC Therapeutics has disclosed Gross Margin across 6 years of filings, most recently posting 89.07% for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 91.59% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 90.43% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 35.86% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 71.60% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 84.20% |
| 10 | ADC Therapeutics | 172.04 Mn | -47.07 Mn | 17.14 Mn | 89.07% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 89.07% |
| Mar 31, 2026 | 83.37% |
| Sep 30, 2025 | 92.68% |
| Jun 30, 2025 | 95.56% |
| Mar 31, 2025 | 91.05% |
| Sep 30, 2024 | 95.39% |
| Jun 30, 2024 | 93.01% |
| Mar 31, 2024 | 86.10% |
| Sep 30, 2023 | 97.47% |
| Jun 30, 2023 | 93.16% |
| Mar 31, 2023 | 96.89% |
| Sep 30, 2022 | 98.30% |
| Jun 30, 2022 | 86.89% |
| Mar 31, 2022 | 98.86% |
| Sep 30, 2021 | 96.18% |
| Jun 30, 2021 | 96.78% |